NCT06010472View on ClinicalTrials.gov

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 20, 2023

Primary Completion Date

August 25, 2026

Study Completion Date

August 25, 2027

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
DRUG

anti-CD19 CAR NK cells (KN5501)

"Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."

Trial Locations (1)

Unknown

RECRUITING

Changhai Hospital, Shanghai

All Listed Sponsors
collaborator

Rui Therapeutics Co., Ltd

INDUSTRY

lead

Changhai Hospital

OTHER